Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California. more
Time Frame | IOVA | Sector | S&P500 |
---|---|---|---|
1-Week Return | -4.85% | -0.94% | -2.6% |
1-Month Return | -19.53% | -5.08% | -1.08% |
3-Month Return | -22.77% | -10.62% | 3.45% |
6-Month Return | -8.58% | -6.18% | 8.57% |
1-Year Return | -16.09% | 1.98% | 24.3% |
3-Year Return | -63% | -0.93% | 25.58% |
5-Year Return | -74.15% | 33.84% | 84.07% |
10-Year Return | -6.75% | 102.52% | 185.12% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | 238.00K | 1.19M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":20.02,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 8.12M | 8.71M | 13.98M | 21.14M | 10.76M | [{"date":"2019-12-31","value":38.43,"profit":true},{"date":"2020-12-31","value":41.22,"profit":true},{"date":"2021-12-31","value":66.15,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":50.89,"profit":true}] |
Gross Profit | (8.12M) | (8.71M) | (13.98M) | (21.14M) | (9.57M) | [{"date":"2019-12-31","value":-812299900,"profit":false},{"date":"2020-12-31","value":-871200000,"profit":false},{"date":"2021-12-31","value":-1398000000,"profit":false},{"date":"2022-12-31","value":-2113500000,"profit":false},{"date":"2023-12-31","value":-956600000,"profit":false}] |
Gross Margin | - | - | - | (8880.25%) | (804.54%) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-8880.25,"profit":false},{"date":"2023-12-31","value":-804.54,"profit":false}] |
Operating Expenses | 206.87M | 261.94M | 342.70M | 398.88M | 450.99M | [{"date":"2019-12-31","value":45.87,"profit":true},{"date":"2020-12-31","value":58.08,"profit":true},{"date":"2021-12-31","value":75.99,"profit":true},{"date":"2022-12-31","value":88.44,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (206.87M) | (261.94M) | (342.70M) | (398.88M) | (460.56M) | [{"date":"2019-12-31","value":-20687200000,"profit":false},{"date":"2020-12-31","value":-26193700000,"profit":false},{"date":"2021-12-31","value":-34270300000,"profit":false},{"date":"2022-12-31","value":-39887800000,"profit":false},{"date":"2023-12-31","value":-46055900000,"profit":false}] |
Total Non-Operating Income/Expense | 18.63M | 4.71M | 902.00K | 5.97M | 24.68M | [{"date":"2019-12-31","value":75.48,"profit":true},{"date":"2020-12-31","value":19.09,"profit":true},{"date":"2021-12-31","value":3.65,"profit":true},{"date":"2022-12-31","value":24.18,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (197.56M) | (259.58M) | (342.25M) | (395.89M) | (447.52M) | [{"date":"2019-12-31","value":-19755600000,"profit":false},{"date":"2020-12-31","value":-25958100000,"profit":false},{"date":"2021-12-31","value":-34225200000,"profit":false},{"date":"2022-12-31","value":-39589300000,"profit":false},{"date":"2023-12-31","value":-44751600000,"profit":false}] |
Income Taxes | (10.48M) | (2.36M) | (14.43M) | (5.97M) | (3.48M) | [{"date":"2019-12-31","value":-1048500000,"profit":false},{"date":"2020-12-31","value":-235600000,"profit":false},{"date":"2021-12-31","value":-1443100000,"profit":false},{"date":"2022-12-31","value":-597000000,"profit":false},{"date":"2023-12-31","value":-347900000,"profit":false}] |
Income After Taxes | (187.07M) | (257.23M) | (327.82M) | (389.92M) | (444.04M) | [{"date":"2019-12-31","value":-18707100000,"profit":false},{"date":"2020-12-31","value":-25722500000,"profit":false},{"date":"2021-12-31","value":-32782100000,"profit":false},{"date":"2022-12-31","value":-38992300000,"profit":false},{"date":"2023-12-31","value":-44403700000,"profit":false}] |
Income From Continuous Operations | (197.56M) | (259.58M) | (342.25M) | (395.89M) | (432.98M) | [{"date":"2019-12-31","value":-19755600000,"profit":false},{"date":"2020-12-31","value":-25958100000,"profit":false},{"date":"2021-12-31","value":-34225200000,"profit":false},{"date":"2022-12-31","value":-39589300000,"profit":false},{"date":"2023-12-31","value":-43297700000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (187.07M) | (257.23M) | (327.82M) | (389.92M) | (444.04M) | [{"date":"2019-12-31","value":-18707100000,"profit":false},{"date":"2020-12-31","value":-25722500000,"profit":false},{"date":"2021-12-31","value":-32782100000,"profit":false},{"date":"2022-12-31","value":-38992300000,"profit":false},{"date":"2023-12-31","value":-44403700000,"profit":false}] |
EPS (Diluted) | (1.58) | (1.89) | (2.22) | (2.48) | (1.88) | [{"date":"2019-12-31","value":-158,"profit":false},{"date":"2020-12-31","value":-189,"profit":false},{"date":"2021-12-31","value":-222,"profit":false},{"date":"2022-12-31","value":-248,"profit":false},{"date":"2023-12-31","value":-188,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
IOVA | |
---|---|
Cash Ratio | 3.37 |
Current Ratio | 4.22 |
Quick Ratio | 3.90 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
IOVA | |
---|---|
ROA (LTM) | -29.16% |
ROE (LTM) | -56.65% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
IOVA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.22 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.78 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
IOVA | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 24.76 |
P/B | 2.91 |
Price/FCF | NM |
EV/R | 21.25 |
EV/Ebitda | NM |
PEG | NM |
Iovance Biotherapeutics Inc (IOVA) share price today is $7.46
Yes, Indians can buy shares of Iovance Biotherapeutics Inc (IOVA) on Vested. To buy Iovance Biotherapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in IOVA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Iovance Biotherapeutics Inc (IOVA) via the Vested app. You can start investing in Iovance Biotherapeutics Inc (IOVA) with a minimum investment of $1.
You can invest in shares of Iovance Biotherapeutics Inc (IOVA) via Vested in three simple steps:
The 52-week high price of Iovance Biotherapeutics Inc (IOVA) is $18.33. The 52-week low price of Iovance Biotherapeutics Inc (IOVA) is $6.7.
The price-to-earnings (P/E) ratio of Iovance Biotherapeutics Inc (IOVA) is
The price-to-book (P/B) ratio of Iovance Biotherapeutics Inc (IOVA) is 2.91
The dividend yield of Iovance Biotherapeutics Inc (IOVA) is 0.00%
The market capitalization of Iovance Biotherapeutics Inc (IOVA) is $2.20B
The stock symbol (or ticker) of Iovance Biotherapeutics Inc is IOVA